Furui Co.,Ltd.(300049.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Furui Co.,Ltd.
300049.SZ
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liver disease; and FibroView data management software.
2.805 T
300049.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking16/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.36%B
    • Profit Margin9.68%B
    • Gross Margin74.89%A
  • Growth ScoreB
    • Revenue YoY19.79%B
    • Net Profit YoY58.51%B
    • Total Assets YoY11.11%B
    • Net Assets YoY13.47%B
  • Cash ScoreB
    • Cash Flow Margin233.95%A
    • OCF YoY19.79%B
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreB
    • Gearing Ratio27.48%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

    MorningStar·
    MorningStar·

    Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

    Yicai·
    Yicai·

    Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

    Zhitong·
    SH
    688566
    +0.49%
    SH
    688136
    -4.30%
    SZ
    002250
    -1.95%
    Zhitong·
    SH
    688566
    +0.49%
    SH
    688136
    -4.30%
    SZ
    002250
    -1.95%

    Furui Co., Ltd: Net profit in the third quarter was 59.9522 million yuan, a year-on-year increase of 125.06%

    Zhitong·
    SZ
    300049
    -0.60%
    Zhitong·
    SZ
    300049
    -0.60%

    Furui Co., Ltd. released its performance for the first half of the year, with a net profit attributable to the parent company of 51.934 million yuan, a decrease of 31.09%

    Zhitong·
    SZ
    300049
    -0.60%
    Zhitong·
    SZ
    300049
    -0.60%
    © 2026 Longbridge｜Disclaimer